- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04243499
First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION)
A First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Paul Frohna, MD, PhD
- Phone Number: 8582055285
- Email: paul.frohna@imcheck.fr
Study Locations
-
-
-
Brussels, Belgium
- Recruiting
- Institut Jules Bordet
-
Principal Investigator:
- Christiane Jungels, MD
-
Contact:
- Joanna Neto
- Email: joana.neto@bordet.be
-
-
-
-
-
Marseille, France
- Recruiting
- Institut Paoli-Calmettes
-
Principal Investigator:
- Norbert Vey, MD
-
Contact:
- Julie Karsenty
- Email: KARSENTYJ@ipc.unicancer.fr
-
Paris, France
- Recruiting
- Gustave Roussy
-
Contact:
- Manare ALI
- Email: Manare.ALI@gustaveroussy.fr
-
Principal Investigator:
- Aurelien Marabelle, MD, PhD
-
-
-
-
-
Dresden, Germany
- Recruiting
- University Carl Gustav Carus Clinical Trial Unit
-
Principal Investigator:
- Martin Wermke, MD
-
Contact:
- Sophia Tischer
- Email: Sophia.Tischer@uniklinikum-dresden.de
-
-
-
-
-
Barcelona, Spain
- Recruiting
- Vall d'Hebron Instiute of Oncology
-
Contact:
- Nuria Farras LLansana
- Email: nfarras@vhio.net
-
Principal Investigator:
- Elena Garralda, MD
-
-
-
-
-
London, United Kingdom
- Recruiting
- Institute of Cancer Research
-
Contact:
- Robert Daly
- Email: robert.daly@icr.ac.uk
-
Principal Investigator:
- Johann de Bono, MD, PhD
-
-
-
-
Connecticut
-
New Haven, Connecticut, United States, 06511
- Recruiting
- Yale Cancer Center
-
Contact:
- Priscilla Steve
- Email: priscilla.steve@yale.edu
-
Principal Investigator:
- Patricia LoRusso, DO,
-
-
Texas
-
Houston, Texas, United States, 77030
- Not yet recruiting
- The University Of Texas MD Anderson Cancer Center
-
Contact:
- Carissa Jurisprudencia
- Email: CGjurisprudencia@mdanderson.org
-
Principal Investigator:
- Abishek Maiti, MD
-
-
Washington
-
Seattle, Washington, United States, 98133
- Recruiting
- University of Washington
-
Principal Investigator:
- Evan Hall, MD
-
Contact:
- Amanda Ramsing-Lund
- Email: aramsing@fredhutch.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Voluntarily signed informed consent form.
Relapsed/refractory patients with histologically or cytologically confirmed diagnosis of advanced-stage or recurrent cancer, including:
Group A: bladder, breast, colon, gastric, melanoma, ovarian, prostate and PDAC Group B: hematologic malignancies including acute myeloid leukemia, acute lymphocytic leukemia, Diffuse large B cell lymphoma and follicular lymphoma Group C: melanoma, cervical, bladder, gastric, head and neck SCC, and lymphoma (according to the approved package labeling of the ICI) Part 2, Group D: Ovarian cancer (2L/3L) with baseline g9d2 T cells > 20K Part 2, Group E: metastatic castrate resistant prostate cancer (2L/3L) with baseline g9d2 T cells > 20K Part 2, Group F: newly diagnosed AML starting venetoclax/azacitidine Part 2, Group G: checkpoint-refractory metastatic melanoma with g9d2 T cells >5K Part 2, Group H: chemotx-refractory or Pt-ineligible urotherlial cancer (bladder) with g9d2 T cells >5K Part 2, Group I: checkpoint-refractory, metastatic HNSCC with g9d2 T cells >5K
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
- Life expectancy > 3 months as assessed by the Investigator
- At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST)/ Response Evaluation Criteria in Lymphoma (RECIL) or >5% marrow blasts
Exclusion Criteria:
- Any malignancy of Vγ9Vδ2 T cell origin
- Any anti-tumor-directed drug therapy within 28 days or 5 times the elimination half-life (whichever is shorter) before study treatment (does not apply to patients receiving ICI for the combination arm)
- Treatment with investigational drug(s) within 28 days before study treatment
- Systemic steroids at a daily dose of > 10 mg of prednisone, > 2 mg of dexamethasone or equivalent, for the last 28 days and need for ongoing treatment.
- Patients with rapidly progressing disease defined as advanced/metastatic, symptomatic, visceral spread, with a risk of life-threatening complications in the short term (e.g., during Screening Period/ treatment washout) that includes patients with massive uncontrolled effusions pleural, pericardial, peritoneal, pulmonary lymphangitis, and over 50% liver involvement
- Ongoing immune-related adverse events (irAEs) and/or AEs ≥grade 2 not resolved from previous therapies except vitiligo, stable neuropathy up to grade 2, hair loss, and stable endocrinopathies with replacement hormone therapy.
- Within 4 weeks of major surgery
- Documented history of active autoimmune disorders requiring systemic immunosuppressive therapy within the last 12 months
- Primary or secondary immune deficiency
- Active and uncontrolled infections requiring intravenous antibiotic or antiviral treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IV ICT01 Monotherapy
Up to six ICT01 dose levels administered as IV monotherapy every 3 weeks will be tested in Part 1 Dose Escalation and up to 2 dose levels in Part 2 Cohort Expansion
|
humanized anti-Butyrophilin 3A (BTN3A) monoclonal antibody
|
Experimental: IV ICT01 + IV Pembrolizumab
A range of IV ICT01 doses administered every 3 weeks will be tested in combination with 200 mg pembrolizumab in Part 1 Dose Escalation and up to 2 dose levels of ICT01 plus 200 mg pembrolizumab in Part 2 Cohort Expansion
|
humanized anti-Butyrophilin 3A (BTN3A) monoclonal antibody
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events (Parts 1 & 2)
Time Frame: 12 months
|
Incidence of treatment-emergent adverse events
|
12 months
|
Disease Control Rate using RECIST for solid tumor patients (Part 2)
Time Frame: 12 months
|
RECIST is measured every 8 weeks during treatment
|
12 months
|
Disease Control Rate using RECIL for lymphoma patients (Part 2)
Time Frame: 12 months
|
RECIL is measured every 8 weeks during treatment
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline in the Number of Circulating Gamma Delta T Cells
Time Frame: 28 days
|
Flow cytometric counting of circulating gamma delta T cells
|
28 days
|
Change from Baseline in the Activation State of Circulating Gamma Delta T Cells
Time Frame: 28 days
|
Flow cytometric measurement of CD69 and Ki67 expression on gamma delta T cells
|
28 days
|
Cmax following the first dose of ICT01
Time Frame: 1 day
|
PK parameter from serum ICT01 levels
|
1 day
|
AUC following the first dose of ICT01
Time Frame: 21 days
|
PK parameter from serum ICT01 levels
|
21 days
|
Clearance at steady-state of ICT01
Time Frame: 6 months
|
PK parameter from serum ICT01 levels
|
6 months
|
Half-life of ICT01
Time Frame: 6 months
|
PK parameter from serum ICT01 levels
|
6 months
|
Objective Response Rate using RECIST for solid tumor patients (Part 2)
Time Frame: 12 months
|
RECIST is measured every 8 weeks during treatment
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Paul Frohna, MD, PhD, ImCheck Therapeutics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- ICT01-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematopoietic/Lymphoid Cancer
-
Leland MethenyAvailableHematopoietic/Lymphoid CancerUnited States
-
University of Colorado, DenverNational Cancer Institute (NCI)CompletedHematopoietic/Lymphoid CancerUnited States
-
M.D. Anderson Cancer CenterAmgenTerminatedHematopoietic/Lymphoid Cancer | Richter's TransformationUnited States
-
University of Colorado, DenverPatient-Centered Outcomes Research InstituteCompletedHematopoietic/Lymphoid CancerUnited States
-
Cancer Research UKUnknownHematopoietic/Lymphoid CancerUnited Kingdom
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)CompletedPain | Hematopoietic/Lymphoid CancerUnited States
-
University of California, San FranciscoSwim Across AmericaRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Childhood CancerUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Cancer | SurvivorshipUnited States
-
Assistance Publique Hopitaux De MarseilleUnknownHematopoietic/Lymphoid CancerFrance
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid System NeoplasmUnited States
Clinical Trials on IV ICT01
-
Taipei City HospitalNot yet recruitingAcute Flank PainTaiwan
-
Healthgen Biotechnology Corp.RecruitingEmphysema Secondary to Congenital AATDUnited States
-
Eli Lilly and CompanyCompletedPsoriasisUnited States
-
Kyowa Kirin Co., Ltd.Terminated
-
Healthgen Biotechnology Corp.Completed
-
Eli Lilly and CompanyCompletedAlzheimer DiseaseUnited States, Japan
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
Asir John SamuelMaharishi Markendeswar University (Deemed to be University)RecruitingAcute Coronary SyndromeIndia
-
WockhardtCompletedBioavailabilityUnited States
-
C. R. BardCompletedVascular Access ComplicationUnited States